Advances in diagnosis and treatment of internal mammary lymph node of breast cancer
10.3969/j.issn.1000-8179.2017.21.641
- VernacularTitle:乳腺癌内乳区淋巴结诊疗的研究进展
- Author:
BI ZHAO
1
,
2
;
山东大学附属山东省肿瘤医院乳腺病中心外科三病区
;
QIU PENGFEI
Author Information
1. 济南大学山东省医学科学院医学与生命科学学院 济南市250200
2. 山东大学附属山东省肿瘤医院乳腺病中心外科三病区
- Keywords:
breast cancer;
internal mammary lymph node;
sentinel lymph node biopsy;
validation
- From:
Chinese Journal of Clinical Oncology
2017;44(21):1104-1107
- CountryChina
- Language:Chinese
-
Abstract:
Internal mammary lymph nodes (IMLN) constitutes approximately 25% of the lymph nodes of the breast. The status of IMLN is one of the prognostic factors in breast cancer patients and essential to regional staging and adjuvant treatment choice. Inter-nal mammary-sentinel lymph node biopsy (IM-SLNB) is deemed a minimally invasive technique for the effective evaluation of IMLN sta-tus and useful in individualized diagnosis and treatment. Injecting radiotracer into glands around the areola through a modified injec-tion technique and at increased injection dose results in the high identification rate of internal mammary sentinel lymph node (IMSLN). Thus, routine IM-SLNB is feasible in clinical practice. Internal mammary lymph drainage pattern is extensively studied, and the accuracy of IM-SLNB guided by modified injection technique is gaining preliminary validation. This review summarizes the progress in diagnosis and treatment of IMLN of breast cancer.
